title: Quantitative assays for hepatitis C virus in serum as predictors of the long-term response to interferon.
abstract: OBJECTIVE
  Interferon therapy has a beneficial effect in patients with chronic hepatitis C who have a low viral load. The aim of this study was to compare the core protein level with HCV RNA levels and to analyze whether virus quantitation predicts the efficacy of interferon therapy.
  
  
  METHODS
  HCV core protein level assessed by the recently developed assay was compared with HCV RNA levels measured by three different methods (Amplicor-HCV monitor, competitive RT(CRT)-PCR, and bDNA probe assay) in 352 patients with chronic hepatitis C in relation to viral serotype.
  
  
  RESULTS
  From 91% (320/352) to 93% (299/322) of patients with viremia were detected by Amplicor-monitor and CRT-PCR, in contrast to 60% (187/312) and 74% (191/258) by bDNA and HCV core protein assay, respectively. The HCV core protein level was positively correlated with HCV RNA levels measured by the three assays (r = 0.680 to 0.731). Serum HCV RNA and core protein levels were significantly lower in patients with serotype 2 than in those with serotype 1. Viral eradication after interferon therapy was observed in 60-70% of the patients with < 1 x 10(4) copies/ml of HCV RNA by Amplicor-monitor assay, < 2 x 10(5) copies/ml by CRT-PCR, < 0.5 Meq/ml by bDNA assay, and < 20 pg/ml of core protein by HCV core protein assay. Viral eradication was uncommon (< 11%) among the patients with higher viral loads. Bivariate analysis revealed that the outcome of interferon therapy was more closely associated with both HCV core protein and RNA levels than the HCV serotype.
  
  
  CONCLUSIONS
  Quantitation of HCV core protein and HCV RNA in useful for prediction of the interferon response.
authors.affiliation: Department of Internal Medicine (II), Faculty of Medicine, University of Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Shiratori
authors.forename: N
authors.initials: N
authors.lastname: Kato
authors.forename: O
authors.initials: O
authors.lastname: Yokosuka
authors.forename: E
authors.initials: E
authors.lastname: Hashimoto
authors.forename: N
authors.initials: N
authors.lastname: Hayashi
authors.forename: A
authors.initials: A
authors.lastname: Nakamura
authors.forename: M
authors.initials: M
authors.lastname: Asada
authors.forename: H
authors.initials: H
authors.lastname: Kuroda
authors.forename: H
authors.initials: H
authors.lastname: Ohkubo
authors.forename: Y
authors.initials: Y
authors.lastname: Arakawa
authors.forename: A
authors.initials: A
authors.lastname: Iwama
authors.forename: M
authors.initials: M
authors.lastname: Omata
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012703:Serotyping; D013997:Time Factors; D014758:Viral Core Proteins / Q000097:blood*
chemical_list: D000998:Antiviral Agents; D014758:Viral Core Proteins; D007372:Interferons